一个有前途的方法:用于阿尔茨海默病的磁性纳米系统
Catarina I P Chaparro1,2, Beatriz T Simões1, João P Borges2
1Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal.
Pharmaceutics
|September 28, 2023
概括
磁纳米粒子 (MNPs) 为阿尔茨海默氏症 (AD) 治疗提供了一个有前途的解决方案,它可以通过血脑屏障 (BBB) 实现向药物输送,并作为MRI对比剂.
科学领域:
- 神经科学和纳米技术
- 生物医学工程 生物医学工程
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,其病因不明确,血脑屏障 (BBB) 阻碍了有效的治疗.
- 目前对中枢神经系统疾病的治疗策略面临挑战,因为药物进入大脑的透率有限,并可能产生副作用.
- 纳米技术提供了多功能平台,纳米颗粒 (NP) 显示了AD治疗学的潜力.
研究的目的:
- 审查基于磁纳米粒子 (MNP) 的系统,用于阿尔茨海默病 (AD) 的治疗.
- 突出表面修饰的MNP在神经向诊断和治疗方面的潜力.
- 探索MNP作为分子成像和药物输送在BBB的双平台.
主要方法:
- 对基于MNP的中枢神经系统药物输送和分子成像系统的审查.
- 讨论表面功能化策略,以加强BBB运输.
- 整合MNP物理属性与面部修改,用于针对性神经异常.
主要成果:
- MNPs可以作为MRI对比剂和药物输送工具.
- MNPs的表面功能化影响与大脑内皮细胞的相互作用,促进BBB交叉.
- 多功能MNP代表了神经向AD治疗术的新策略.
结论:
- 基于MNP的系统为诊断和治疗AD等神经退行性疾病提供了一个有前途的双重方法.
- 表面修改对于优化MNP与BBB的相互作用和增强大脑透至关重要.
- 随着MNP技术的进一步进步,未来的AD治疗术具有显著的潜力.
相关概念视频
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
Alzheimer's Disease: Overview
513
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
513


